Asia-Pacific Smoking cessation and nicotine de-addiction market is projected to register 30.7% CAGR in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Asia-Pacific Smoking Cessation and Nicotine De-Addiction Market-By Product Type (With Nicotine and Without Nicotine), Treatment Type (Pharmacological, Therapies and Others) Distribution Channel (Online, Offline), End-User (Generation Z, Millennials, Generation X and Silent Generation), Country (Japan, China, South Korea, India, Australia and New Zealand, Taiwan, Hong-Kong, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific)-Industry Trends and Forecast to 2027.
Some of the major factors contributing to the growth of the Asia-Pacific smoking cessation and nicotine de-addiction market:
- Smokers in the area are very wide and competition for nicotine drugs is growing in order to encourage prevention of smoking
- Large number of retail store for medicines or solutions
Market Players:
The key players of Asia-Pacific smoking cessation and nicotine de-addiction market are:
- Pfizer Inc.
- Dr. Reddy’s Laboratories Ltd
- Glaxosmithkline Plc.
- British American Tobacco
- Cipla Inc.
- Fertin Pharma
- Japan Tobacco Inc.
- Johnson & Johnson Services, Inc.
- Strides Consumer Private Limited
- Takeda Consumer Healthcare Company Limited